A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination

Cancer Research

Volumn 66, Issue 15, 2006, Pages 7532-7539

  Yanagihara, Kazuyoshi ^a   Takigahira, Misato ^a   Takeshita, Fumitaka ^a   Komatsu, Teruo ^a   Nishio, Kazuto ^a   Hasegawa, Fumio ^a   Ochiya, Takahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OMENTUM; ORTHOTOPIC TRANSPLANTATION; PATHOLOGICAL ANATOMY; PERITONEUM TUMOR; PHOTON ABSORPTIOMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROSA; STRUCTURE ANALYSIS; SUBMUCOSA; TUMOR GROWTH;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUCIFERASES; MICE; MICE, INBRED BALB C; MICE, NUDE; PERITONEAL NEOPLASMS; PHOTONS; STOMACH NEOPLASMS; TRANSFECTION;

EID: 33747890094     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3259     Document Type: Article

References (49)

1. Chu ZD, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecological malignancy. A prospective study of prognostic factors. Cancer 1989;63:364-7.
2. Moriguchi S, Maehara Y, Korenaga D, et al. Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. Surg Oncol 1992;1:341-6.
3. Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996;83:726-33.
4. Tanahashi H, Konishi M, Nakagohri T, et al. Aggressive multimodal treatment for peritoneal dissemination and needle tract implantation of hepatocellular carcinoma: a case report. Jpn J Clin Oncol 2004;34:551-5.
5. Heintz AP. Surgery in advanced ovarian carcinoma: is there proof to show the benefit? Eur J Surg Oncol 1988;14:91-9.
6. Hoskins WJ. Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl 1995;33:189-99.
7. Kaibara N, Iitsuka Y, Kimura A, et al. Relationship between area of serosal invasion and prognosis in patients with gastric carcinoma. Cancer 1987;60:136-9.
8. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 1994;73:2048-52.
9. Katano M, Morisaki T. The past, the present, and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 1998;18:3917-25.
10. Kotanagi H, Saito Y, Shinozawa N, Koyama K. Establishment of a human cancer cell line with high potential for peritoneal dissemination. J Gastroenterol 1995;30:437-8.
11. Kaneko K, Yano M, Tsujinaka T, et al. Establishment of a visible peritoneal micrometastatic model from a gastric adenocarcinoma cell line by green fluorescent protein. Int J Oncol 2000;16:893-8.
12. Nomura H, Nishimori H, Yasoshima T, et al. A novel experimental mouse model of peritoneal dissemination of human gastric cancer cells: analysis of the mechanism of peritoneal dissemination using cDNA macroarrays. Jpn J Cancer Res 2001;92:748-54.
13. Furukawa T, Fu X, Kubota T, et al. Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 1993;53:1204-8.
14. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
15. Yashiro M, Chung YS, Nishimura S, et al. Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 1996;14:43-54.
16. Yanagihara K, Tanaka H, Takigahira M, et al. Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci 2004;95:575-82.
17. Yanagihara K, Takigahira M, Tanaka H, et al. Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. Cancer Sci 2005;96:323-32.
18. 1 subunit antibody. Jpn J Cancer Res 1992;83:1317-26.
19. Nakashio T, Narita T, Akiyama S, et al. Adhesion molecules and TGF-β1 are involved in the peritoneal dissemination of NUGC-4 human gastric cancer cells. Int J Cancer 1997;70:612-8.
20. 4 as a suppressor and a predictive marker for peritoneal dissemination in human gastric cancer. Gastroenterology 2000;118:497-506.
21. Nishimura S, Adachi M, Ishida T, et al. Adenovirus-mediated transfection of caspase-8 augments anoikis and inhibits peritoneal dissemination of human gastric carcinoma cells. Cancer Res 2001;61:7009-14.
22. Minagawa A, Otani Y, Kubota T, et al. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn J Cancer Res 2001;92:1322-8.
23. Kimata M, Otani Y, Kubota T, et al. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 2002;93:834-41.
24. Piso P, Aselmann H, von Wasielewski R, et al. Prevention of peritoneal carcinomatosis from human gastric cancer cells by adjuvant-type intraperitoneal immunotherapy in a SCID mouse model. Eur Surg Res 2003;35:470-6.
25. Yonemura Y, Endou Y, Bando E, et al. Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer. Cancer Lett 2004;210:189-96.
26. Chishima T, Miyagi Y, Wang X, et al. Cancer invasion and micrometastasis visualized in live tissue by green fluorescent protein expression. Cancer Res 1997;57:2042-7.
27. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 2005;5:796-806.
28. Hasegawa S, Yang M, Chishima T, et al. In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis. Cancer Gene Ther 2000;7:1336-40.
29. Bouvet M, Wang J, Nardin SR, et al. Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthotopic model. Cancer Res 2002;62:1534-40.
30. Sun F-X, Tohgo A, Bouvet M, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res 2003;63:80-5.
31. Nakanishi H, Mochizuki Y, Kodera Y, et al. Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci 2003;94:112-8.
32. Ray P, De A, Min JJ, et al. Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 2004;64:1323-30.
33. Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol Med 2005;111:297-322.
34. Nakanishi H, Ito S, Mochizuki Y, Tatematsu M. Evaluation of chemosensitivity of micrometastases with green fluorescent protein gene-tagged tumor models in mice. Methods Mol Med 2005;111:351-62.
35. Hennig R, Ventura J, Segersvard R, et al. LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice. Neoplasia 2005;7:417-25.
36. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. Nat Med 1998;4:245-7.
37. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000;2:491-5.
38. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003;20:733-44.
39. Vooijs M, Jonkers J, Lyons S, Berns A. Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 2002;62:1862-7.
40. Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177-82.
41. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005;205:194-205.
42. Hiraga T, Williams PJ, Ueda A, et al. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10:4559-67.
43. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res 2005;11:7569-78.
44. Arao T, Yanagihara K, Takigahira M, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 2006;118:483-9.
45. El Hilali N, Rubio N, Martinez-Villacampa M, Blanco J. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab Invest 2002;82:1563-71.
46. Burgos JS, Rosol M, Moats RA, et al. Time course of bioluminescent signal in orthotopic and heterotopic brain tumors in nude mice. Biotechniques 2003;34:1184-8.
47. Yanagihara K, Seyama T, Tsumuraya M, et al. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991;51:381-6.
48. Yanagihara K, Kajitani T, Kamiya K, Yokoro K. In vitro studies on the mechanism of leukemogenesis-I. Establishment and characterization of cell lines derived from the thymic epithelial reticulum cell of the mouse. Leuk Res 1981;5:321-9.
49. Domagala W, Koss LG. Surface configuration of mesothelial cells in effusions. A comparative light microscopic and scanning electron microscopic study. Virchows Arch B Cell Pathol Incl Mol Pathol 1979;30:231-43.